DC Circ. Boosts Teva In Row With FDA Over Merck Drugs

Law360, New York (March 2, 2010, 7:09 PM EST) -- Teva Pharmaceutical Industries Ltd. has been given a renewed shot at the market for hypertension drugs, with a federal appeals court granting the Israeli drugmaker 180 days to exclusively sell its generic versions of Merck & Co.'s popular losartan potassium products Hyzaar and Cozaar.

In a ruling Tuesday, the U.S. Court of Appeals for the District of Columbia Circuit overturned a lower court's decision that Teva had forfeited its exclusivity rights, agreeing with Teva that it should be entitled to the six-month period.

The case marks...
To view the full article, register now.